Valo Therapeutics Acquires University Of Helsinki´s Technology That Capitalizes On Pre-existing Immunity Acquired Via Childhood Vaccination Programs To Potentiate The Efficacy Of Cancer Treatment

Published by
The Street

By PR Newswire HELSINKI, Jan. 6, 2022 /PRNewswire/ — Valo Therapeutics Oy (ValoTx), the developer of novel, adaptable immunotherapy platforms for cancer and infectious diseases, today announced the acquisition of intellectual property rights from the University of Helsinki, Finland, for the proprietary technology which utilises pre-existing immunity (PEI) against pathogens to enhance the therapeutic efficacy of ValoTx´s lead platform, PeptiCRAd. This innovative approach takes advantage of existing acquired immunity (generated, for example, through vaccination against pathogens) by including p…

Read More

Leave a Reply

Your email address will not be published. Required fields are marked *